You are here: Home » PTI Stories » National » News
Business Standard

Cipla partners with Eli Lilly to market diabetes drug Basaglar in India

Press Trust of India  |  New Delhi 

Drug firm today said it has partnered with to market and distribute Lilly's glargine injection, Basaglar, in

Cipla's tie up is with and Company (India) Pvt Ltd, a 100 per of the US based firm, the two firms said in a joint statement.

The companies did not disclose the financial details of the deal.

expects to start commercialising Basaglar in by end of this year.

MD & said: "continues to be a focus area for Cipla and with the launch of strong brand like Basaglar, Cipla will be at the forefront of providing a care with the most comprehensive portfolio across orals and injectables."

The company's focus continues to revolve around care continuum approach for the patients it serves and create greater access to high quality treatment and medication, he added.

Lilly MD said: "This strategic partnership leverages Lilly's commitment to bring innovation to people suffering from in India and Cipla's strong on-ground footprint across the country."

Cipla stock was trading 2.22 per cent up at Rs 552.25 on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, June 08 2018. 13:35 IST